| Literature DB >> 28894229 |
Wen-Chin Weng1,2, Kuan-Hung Lin2, Pei-Yi Wu3, Ya-Hsuan Ho2, Yen-Lin Liu1,4, Bo-Jeng Wang3, Chien-Chin Chen5,6, Yueh-Chien Lin2, Yung-Feng Liao3, Wang-Tso Lee1, Wen-Ming Hsu7, Hsinyu Lee8,9,10,11,12.
Abstract
Neuroblastoma (NB) is a childhood cancer with a low survival rate and great metastatic potential. Vascular endothelial growth factor (VEGF), an angiogenesis factor, has been found to be involved in CRT-related neuronal differentiation of NB cells. In this study, we further confirmed the role VEGF in NB through mouse xenograft model and clinical analysis from NB patients. In xenograft experiments, CRT overexpression effectively inhibited the tumor growth. In addition, the mRNA and protein levels of VEGF and differentiation marker GAP-43 were upregulated by induced CRT expression. However, no significant correlation between the expression level of VEGF and microvessel density was observed in human NB tumors, suggesting a novel mechanism of VEGF participating in NB tumorigenesis through an angiogenesis-independent pathway. In NB patients' samples, mRNA expression levels of CRT and VEGF were positively correlated. Furthermore, positive VEGF expression by immunostaining of NB tumors was found to correlate well with histological grade of differentiation and predicted a favorable prognosis. In conclusion, our findings suggest that VEGF is a favorable prognostic factor of NB and might affect NB tumor behavior through CRT-driven neuronal differentiation rather than angiogenesis that might shed light on a novel therapeutic strategy to improve the outcome of NB.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28894229 PMCID: PMC5593816 DOI: 10.1038/s41598-017-11637-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1VEGF expression was positively correlated with CRT expression and differentiated histology in human NB tumors. (A) CRT and VEGF mRNA expressions in 56 human NB tumors were determined by real-time PCR and normalized to the internal control GAPDH. The correlation between expression levels of CRT (x axis) and VEGF (y axis) was analyzed by Spearman’s correlation test (Spearman’s ρ = 0.648, P < 0.001). (B) CRT and VEGF mRNA levels in 31 NB tumors were evaluated by real-time PCR. The levels of CRT (shaded bar) and VEGF (solid bar) are higher in differentiated NB (DNB) than in undifferentiated NB (UNB). (C) The CRT mRNA expression was determined by real-time PCR in 56 human NB tumors and presented as the mean ± SEM of each group, undifferentiated NB (N = 27) versus differentiated NB (N = 29). The CRT mRNA expression was significantly increased in differentiated NB. (D) The VEGF mRNA expression was determined by real-time PCR in 56 human NB tumors and presented as the mean ± SEM of each group, UNB (N = 27) versus DNB (N = 29). The VEGF mRNA expression was significantly increased in differentiated NB. **P < 0.01, ***P < 0.005.
Figure 2VEGF expression was positively correlated with CRT expression and neuronal differentiation in NB cells and NB xenografts. (A) Human stNB-V1 NB cells were stimulated with 1 μg/ml tetracycline to induce CRT expression. Expression of CRT, VEGF and GAP43 was visualized and quantitated by immunofluorescence microscopy and ImageJ. Data are shown as mean fluorescence intensity (±SD) from at least three independent experiments. (B,C) Inducible-CRT stNB-V1 cells were injected subcutaneously into nude mice. Tumor inoculated mice were treated with doxycycline in their daily drinking water (2 g/L) to induce CRT expression. Mice were sacrificed after 15-days treatment and the tumor was removed for experiments. The mRNA expression levels of CRT, VEGF, and GAP43 were confirmed by real-time PCR and were increased after doxycycline treatment. The mRNA expression level was normalized to the internal control HSP60. Each bar of the histogram represents quantified results and is shown as the mean ± SD. Statistical differences were compared with the control level. The expressions of CRT, VEGF and GAP43 were visualized and quantitated by immunofluorescence microscopy. *P < 0.05, **P < 0.01.
Figure 3CRT expression suppressed NB tumor growth in mouse xenograft model. (A) Inducible-CRT stNB-V1 cells were employed in mouse xenograft model. NB cells inoculated mice were treated with doxycycline in their daily drinking water (2 g/L) to induce CRT expression. The growth of tumor was measured for 15 days. (B) Tumor inoculated mice were sacrificed after 15-days treatment and the tumor were dissected to measure the tumor size. Statistical differences were compared with the control level. **P < 0.01.
Figure 4VEGF expression correlated with the histology grades of NB tumors and predicted a favorable clinical outcome of NB patients. (A) Immunohistochemical analysis of VEGF expression in tumor tissues of NB patients. Tumors were classified into four categories based on the intensity of VEGF immunostaining: negative, weak, moderate, and strong signals of VEGF. Upper panels shows low magnification images (200× , scale bar, 5 µm) and lower panels indicates the boxed images with high magnification (400× , scale bar, 2 µm). UNB, undifferentiated neuroblastoma. DNB, differentiated neuroblastoma. (B) The correlation between VEGF expression level and the differentiation histology of NB tumor was analyzed in 69 human NB tumor samples. Summation of weak, moderate and strong VEGF immunostaining was recorded as “positive”, thereby 23.5% and 54.3% positive VEGF expression were found in UNB and DNB, respectively. (C) Kaplan-Meier survival analysis according to the expression of VEGF determined by immunohistochemistry in a cohort of 69 NB patients. NB patients with positive VEGF expression in tumor tissues had a significantly higher 5-year predictive survival rate compared to those patients with negative VEGF expression.
VEGF expression and clinicopathologic and biologic characteristics of NB.
| Cases | Positive VEGF expression (%) |
| |
|---|---|---|---|
| Age at diagnosis | |||
| ≤1.5 year | 22 | 11 (50.0) | 0.290 |
| >1.5 year | 47 | 16 (34.0) | |
| Sex | |||
| Male | 37 | 13 (35.1) | 0.621 |
| Female | 32 | 14 (31.1) | |
| Clinical Stage | |||
| 1, 2, 4S | 24 | 13 (54.2) | 0.075 |
| 3, 4 | 45 | 14 (31.1) | |
| Histology | |||
| Undifferentiated | 34 | 8 (23.5) | 0.013 |
| Differentiated | 35 | 19 (54.3) | |
| MYCN | |||
| Amplified | 15 | 2 (13.3) | 0.034 |
| Non-amplified | 54 | 25 (46.3) | |
| CRT expression | |||
| Positive | 31 | 19 (61.3) | 0.001 |
| Negative | 38 | 8 (21.1) | |
| Microvessel density | |||
| High | 35 | 13 (37.1) | 0.808 |
| Low | 34 | 14 (41.2) | |
*Chi-square test.
Figure 5Microvessel density does not correlate with the histology grade of NB tumors. Shown are representative images of microvessels and quantitative data of microvessel density in UNB (N = 21) and DNB (N = 42) tumors staining with blood vessel marker CD34. Data show the mean ± SD. Scale bar, 2 μm.